CS MEDICA A/S: Update on CBD activity research and future patent

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces that one of two hypotheses on CBD activity in the human body has successfully been proven.

In CS MEDICA’s continually research on the efficacy of cannabinoids from the cannabis plant, the Company evaluates the current market of CBD isolate (98% pure CBD) and sourced CBD Isolate, from different manufacturers meeting their preliminary requirements of quality, and research the efficacy of the different sourced CBD in the human body.

The Company believes that the research on the efficacy of CBD and other cannabinoids is the key to the future of the cannabis business for the company and in general for the market and in the end for the patients receiving a product that holds high efficacy and high quality with few-to-none side effects.

CBD isolate investigation & pilot study
In the investigation of the difference between the various CBD isolates tested in the pilot study, CS MEDICA found that the specifications of the CBD Isolate were identical, but when the CBD structure was studied on a micro level, it was discovered that the structure was not identical.

In further studies on the difference between the natural CBD isolates it was discovered that the production process has an impact on the CBD activity. The current knowledge of triggers in the natural CBD has been implemented in CS MEDICA’s PCT patent application (The International Patent System - covering 153 countries) a continuations of the patent application earlier submitted to DK.

One of the last two hypotheses successfully proven
CS MEDICA’s R&D department has continued the research and has conducted several studies together with Leading European Research Laboratories and Special Laboratory Accredited for CBD research to identify the trigger in the natural CBD for being active or inactive for the body. The company has now concluded successfully one of the two last hypotheses, and further studies and test will be performed on the last hypothesis. The Company expects to have performed the final tests during spring of 2023.

Future patent on active CBD
Once these studies and test have been concluded and the hypothesis has been successfully proven, CS MEDICA will develop a new patent application, which will be filed with the patent office. As this know-how is based on basic research, this patent is expected to impact the CBD market on a global scale, hence the Company aims to be acknowledged as a strong CBD research Company in the market, with a technology/know-how other Companies can utilize.

Information about the Chief Scientific Officer (CSO) in CS MEDICA
The R&D department in CS MEDICA is led by CEO & CSO Lone Henriksen, a biochemist who holds a Bachelor of Engineering from the Technical University of Denmark (DTU) and a bachelor in marketing from Copenhagen Business School (CBS). Lone has more than 20 years of experience in the pharmaceutical industry; in product development, purchasing, sales, R&D, and quality management. In her previous work, she was, amongst others, behind the global cooperation between Brenntag and Astra Zeneca. On a management level, she has experience with the following: 

• R&D and QA together with customers & suppliers
• Product Development with customers and vendors within Big Pharma, e.g., Novo, Astra Zeneca, Leo, Pharma Cosmos, Pitzer, etc.
• Sourcing new producers with new niche products 
• Contract and price negotiations 
• Ensuring GMP & GDP in the value chain
• Networking and corporation with global CMOs and labs

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company committed to improving people's lives with products that make a difference. We combine science, nature, and passion to deliver innovative alternatives with high efficacy and bioavailability to patients. From autoimmune to stress therapies, we aim to transform healthcare with more effective treatments.

We research, develop, manufacture, commercialize and brand over-the-counter (OTC) products under pharmaceutical legislation. Currently, 21 products with cannabidiol aimed at autoimmune and stress-related diseases have been developed. The first products reached Danish stores in 2020, and now 9 products are available on the European market at more than 500 points of sale. Another 12 products will be launched before the end of 2024, with 11 patent-pending products. The product line surpasses competing products on the market by being located at the intersection of natural products, science, and cannabinoid technology while being registered under pharmaceutical legislation.

CS MEDICA was recognized earlier this year as a company of Europe's top 10 MedTech companies at European Lifestars Awards as the company both Research & Develop, Manufacture, Distribute and Brand life-supporting medical technologies. The additional research and innovation to develop cutting-edge CBD technologies allow us to lead in CBD medical advancements.

Tags: